It is interesting to note that several SSAO/VAP-1 inhibitors have exhibited anti-obesity properties in animal models [18], and the inhibitor, semicarbazide, is known to limit body mass gain and adiposity [19]. The gene discussed is AOC3; the disease is obesity due to melanocortin 4 receptor deficiency.